NSE-listed pharmaceutical companies providing contract development and manufacturing (CDMO) services to global drug innovators — from custom API synthesis and high-potency molecules to biologics, peptides, and oligonucleotide intermediates.
Sectors represented: Healthcare
RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. . Risingshareofbiologicsalongwithincreasinginvestmentsin. biologicsfornewnichemodalities CDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. .
By prioritizing consistent innovation, the Company is among the few scaled Indian organizations offering both Contract Research Organisation. (CRO) and Contract Development and Manufacturing Organization (CDMO) capabilities for small molecules. ompany is among the few scaled Indian organizations offering both Contract Research Organisation.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. locate resources. more effectively toward innovation and commercial. growth. This shift is further reinforced by transitioning to. an asset-light model, which reduces operating and capital. expenditures. By leveraging CDMOs' streamlined procedures.
GLOBAL PRESENCE. Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg. ACITIES. CLOSE PROXIMITY. TO CLIENTS WITH. GLOBAL PRESENCE. Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg.
Long-term partnerships and strategic outsourcing models. continue to gain traction across the industry. initiatives are creating. opportunities for established CRDMO partners globally. Long-term partnerships and strategic outsourcing models. continue to gain traction across the industry. The Contract Research, Development and Manufacturing Organisation.
CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS). ❏EHS and Quality are the highest priority. nue. CDMO / CMO. 8. ❏Sustainable supply for APIs/NCEs/Intermediates in commercial scale. ❏Global regulatory accreditations (USFDA ,EUGMP, EDQM, KFDA, COFEPRIS).
Akums revenue. 4. IndianCDMO Market. Source: Frost and Sullivan Report on Indian Pharma CDMO (details in Akums RHP). 5. Indian Pharma Market. (INR ‘000 Cr.). Large Indian domestic pharma. opportunity. 132. 198. 285 revenue. 4. IndianCDMO Market. Source: Frost and Sullivan Report on Indian Pharma CDMO (details in Akums RHP). 5. Indian Pharma Market. (INR ‘000 Cr.). Large Indian domestic pharma.
Oligonucleotide and mRNA building blocks including. specific delivery systems and Tri-cyclo-DNA. cGMP on track to be commercially ready; aligned. customer audits to validated the plant being scheduled. Pharma CDMO. 39%. of Sales. API++. 49% of Sales. #% of sales 9MFY26. OUR GROWTH ENGINES -PHARMA CDMO KEY DRIVER. C hance. 00 mmercially ready; aligned.
The global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued. at US$166.0 Billion in 2025 and projected to reach US$293.6 Billion global pharmaceutical contract development and manufacturing. organisation (CDMO) market is experiencing significant growth, valued.